Cargando…
Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer
BACKGROUND: Systemic FOLFOX (folinic acid (leucovorin (LV)), 5-fluorouracil (5-FU), and oxaliplatin), FOLFIRI (LV, 5-FU, and irinotecan), or FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) chemotherapy regimens and additional molecular-target treatments, including anti-vascular endothelial...
Autores principales: | Goi, Takanori, Naruse, Takayuki, Kimura, Youhei, Fujimoto, Daisuke, Morikawa, Mitsuhiro, Koneri, Kenji, Yamaguchi, Akio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600220/ https://www.ncbi.nlm.nih.gov/pubmed/26452624 http://dx.doi.org/10.1186/s12957-015-0704-5 |
Ejemplares similares
-
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report)
por: Sawai, Katsuji, et al.
Publicado: (2013) -
RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer
por: Fujimoto, Daisuke, et al.
Publicado: (2018) -
Five-Year Survival of Alpha-Fetoprotein-Producing Gastric Cancer with Synchronous Liver Metastasis: A Case Report
por: Koneri, Kenji, et al.
Publicado: (2013) -
Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer
por: Goi, Takanori, et al.
Publicado: (2015) -
Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer
por: Takanori, Goi, et al.
Publicado: (2011)